21 December 2013
Amman - Hikma Pharmaceutical founder and chairman, Samih Darwazah, was recently selected as being the first on the Emerging Markets' Leaders of the Scrip 100 list.
A statement released by Hikma on Sunday said that The Scrip 100 list recognizes company heads who are shaping the future of pharma in their respective countries. Besides, it looks for those that are leading the industry through this transformative period.
It includes, in addition to Darwazah, a number of significant emerging market pharmaceutical leaders such as Bill and Melinda Gates for the Gates Foundation, Takeda's Head of Commercial Operations, and the CEO of Samsung Biologics.
Darwazah founded Hikma Pharmaceuticals in 1978 after receiving his Masters degree in Industrial Pharmacy from St. Louis College of Pharmacy, Missouri.
Hikma Pharmaceuticals is a leading pharmaceutical firm keen on developing, manufacturing and marketing quality medication. Its operations are conducted through three businesses: "Branded", "Injectables" and "Generics," and it is based principally in the MENA region, where it is a market leader, the United States and Europe.
The Scrip 100 is a list of the top 100 leaders in the pharmaceutical business and is compiled by the Scrip editorial team. The top 100 leaders selected include philanthropists, regulators and company heads.
The final decision about inclusion came after much discussion and debate that involved a global view of the biopharmaceutical industries.
Amman - Hikma Pharmaceutical founder and chairman, Samih Darwazah, was recently selected as being the first on the Emerging Markets' Leaders of the Scrip 100 list.
A statement released by Hikma on Sunday said that The Scrip 100 list recognizes company heads who are shaping the future of pharma in their respective countries. Besides, it looks for those that are leading the industry through this transformative period.
It includes, in addition to Darwazah, a number of significant emerging market pharmaceutical leaders such as Bill and Melinda Gates for the Gates Foundation, Takeda's Head of Commercial Operations, and the CEO of Samsung Biologics.
Darwazah founded Hikma Pharmaceuticals in 1978 after receiving his Masters degree in Industrial Pharmacy from St. Louis College of Pharmacy, Missouri.
Hikma Pharmaceuticals is a leading pharmaceutical firm keen on developing, manufacturing and marketing quality medication. Its operations are conducted through three businesses: "Branded", "Injectables" and "Generics," and it is based principally in the MENA region, where it is a market leader, the United States and Europe.
The Scrip 100 is a list of the top 100 leaders in the pharmaceutical business and is compiled by the Scrip editorial team. The top 100 leaders selected include philanthropists, regulators and company heads.
The final decision about inclusion came after much discussion and debate that involved a global view of the biopharmaceutical industries.
© Jordan News Agency - Petra 2013
